Oculis (NASDAQ:OCS) Stock Price Up 9% – Still a Buy?

Oculis Holding AG (NASDAQ:OCS) shares rose 9% during mid-day trading on Tuesday . The company traded as high as $11.63 and last traded at $11.6790. Approximately 240,161 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 496,844 shares. The stock had previously closed at $10.71.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Stifel Nicolaus dropped their price target on shares of Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. JPMorgan Chase & Co. lowered their target price on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 3rd. HC Wainwright reduced their target price on Oculis from $47.00 to $26.00 and set a “buy” rating for the company in a report on Monday, June 1st. Finally, Robert W. Baird cut their target price on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research note on Monday, June 1st. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.33.

Oculis Stock Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18. The company has a 50 day moving average price of $26.16 and a 200 day moving average price of $24.92. The company has a market capitalization of $627.15 million, a PE ratio of -5.08 and a beta of 0.23.

Oculis (NASDAQ:OCS) last issued its earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The company had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. Equities analysts forecast that Oculis Holding AG will post -2.27 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after acquiring an additional 6,384 shares during the period. Marshall Wace LLP acquired a new stake in Oculis during the 2nd quarter worth about $393,000. Bank of America Corp DE boosted its position in Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after acquiring an additional 878 shares during the period. Woodline Partners LP boosted its position in Oculis by 65.8% during the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after acquiring an additional 33,265 shares during the period. Finally, Aventura Private Wealth LLC acquired a new stake in Oculis during the 4th quarter worth about $80,000. 22.30% of the stock is owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.